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ABSTRACT
Objective: To estimate the burden of diabetes mellitus (DM) and its com-
plications in The Netherlands.
Methods: The PHARMO Record Linkage System comprised among
others linked drug dispensing, hospital and clinical laboratory data from
approximately 2.5 million individuals in The Netherlands. Patients with
DM (type 1 and type 2) were included in the study cohort from 2000 to
2004 if they used antidiabetic drugs or had HbA1c  6.5 mmol/L or had
a hospitalization for DM or a diabetic complication in the measure-
ment year or in the preceding year. Controls, deﬁned as subjects without
a diagnosis of DM and/or subjects not prescribed glucose-lowering
medication, were 1:1 matched to patients with diabetes, on birth
year, zip code, and gender. Complications (hospitalizations and dispens-
ings for cardiovascular disease/eye problems/amputations) were classi-
ﬁed into stages. Complications attributed to DM were estimated
as complication stages 1 and 2 among patients minus those among
controls. Drug costs were extrapolated to The Netherlands by direct
standardization.
Results: Among the total population in The Netherlands, the prevalence
of DM increased from 2.8% in 2000 to 4.0% in 2004. Severe cardiovas-
cular complications attributed to DM increased from 18,000 to 39,000
patients. Per DM patient the cost of direct treatment attributed to DM
increased from €974 in 2000 to €1283 in 2004. Per 100 members of the
total population, this increase was from €2764 in 2000 to €5140 in 2004.
Most of these costs (65% in 2004) were because of hospitalizations.
Conclusion: Drug treatment, hospitalizations, and cost attributed to dia-
betes mellitus have almost doubled between 2000 and 2004, but so did the
“background” costs in the general population, perhaps because of preven-
tive efforts.
Keywords: diabetes mellitus, diabetes-related complications, direct costs,
pharmacy, prevention and control.
Introduction
The prevalence of diabetes mellitus (DM) worldwide, especially
of type 2 diabetes, is rising rapidly [1]. As for The Netherlands,
data from the Dutch National Institute for Public Health and the
Environment suggest that the annual number of patients with
DM rose from 460,000 in 2000 to approximately 650,000 in
2004 and continues to rise [2]. The impact of DM complications,
drug treatment, and hospitalizations on the total burden of this
disease in the European and Dutch context has not fully been
described. These factors are essential to a complete understand-
ing of the economic burden of this disease.
Diabetic complications, particularly macrovascular complica-
tions including cardiovascular disease and common coexisting
conditions such as hypertension and dyslipidemia are major
causes of disease and mortality among patients with DM [3–6].
The ultimate goal of drug treatment of DM is driven by preven-
tion of these complications in such a way that ultimately there
would be no differences in cardiovascular complications between
diabetic patients and nondiabetic subjects.
Few epidemiological studies are able to measure the impact of
pharmacological intervention on outcomes of DM over longer
periods of time. This is why, among others, prevalence of DM and
its complications have typically been estimated using pharmaco-
economic simulation models, for example, the well-deﬁned and
validated CORE diabetes model [7–9]. Nevertheless, such esti-
mates do not always take into account what background risk of
cardiovascular disease may exist in the general population with or
without overt DM.When this is done, the burden complications in
a population attributed to DM can be elucidated [10].
The objective of this study was therefore to estimate the
annual prevalence, the frequency of complications, treatment,
and hospitalizations, and direct medical costs attributed to DM,
for the period 2000 to 2004 in The Netherlands.
Methods
Study Design
A historical follow-up study was conducted among patients with
DM (type 1 and type 2) compared to matched control subjects
without a diagnosis of DM and/or subjects not prescribed
glucose-lowering medication.
Setting
Data for this study were obtained from the PHARMO Record
Linkage System (PHARMO RLS, Utrecht, The Netherlands),
which includes, among other databases, the drug-dispensing
records from community pharmacies linked on a patient level to
hospital discharge and clinical laboratory records of approxi-
mately 2.5 million individuals in deﬁned areas of The Nether-
lands. These regions are representative of all of The Netherlands
[11]. The computerized drug-dispensing histories contain data
concerning the dispensing date, the prescriber, the prescribed
dosage regimen, the dispensed quantity, and the estimated legend
duration of use. All drugs are coded according to the Anatomical
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Therapeutic Chemical (ATC) classiﬁcation. The hospital records
include detailed information concerning the primary and second-
ary discharge diagnoses, procedures, and dates of hospital admis-
sion and discharge. All diagnoses are coded according to the
International Classiﬁcation of Diseases, 9th edition (ICD-9-CM).
The clinical laboratory records comprise all requests issued by
general practitioners and medical specialists. All tests, processed
by auto-analyzers directly linked to the clinical laboratory com-
puter, are routinely validated and recorded independently of the
test results or physician.
Patient and Control Selection
All patients with DM (type 1 and type 2) from January 1, 2000
to December 31, 2004 were included as patients. Patients were
deﬁned as diabetic if they used “drugs used in diabetes” (ATC
code A10) or had HbA1c  6.5 mmol/L or had a hospitalization
for DM (ICD-9-CM codes 250, 251.0–251.4) in the measure-
ment year or in the preceding year. Cardiovascular complications
were deﬁned as having a diagnosis of ischaemic heart disease
(ICD-9-CM codes 410–414), cerebrovascular accident (ICD-
9-CM codes 430–438), peripheral artery disease (ICD-9-CM
code 443.9) or hypertension (ICD-9-CM codes 401–405) or
based on antihypertensive use (ATC code C02, C03, C07, C08,
C09).
The control group comprised subjects without a diagnosis of
DM and/or subjects not prescribed glucose-lowering medication
who were 1:1 matched on year of birth, zip code, eligibility
status, and gender to patients with DM. Subjects were eligible for
selection as controls if they were present and alive in the database
at the cohort entry date of the corresponding case (= index date).
Cases and controls were followed from the index date to the end
of 2004, death, or moving out of the PHARMO area, whichever
came ﬁrst.
Classiﬁcation of Diabetic Complications
Diabetic complications, including macrovascular and microvas-
cular complications, were classiﬁed into stages 0, 1, or 2 accord-
ing to a modiﬁcation and extension of the classiﬁcation proposed
by Brown et al. [12]. Brieﬂy, the classiﬁcation involved no evi-
dence of complications (stage 0), preevent treatment (stage 1),
and postevent cardiovascular diseases (stage 2). Stage 1 was
assigned if cardiovascular medications (lipid-lowering drugs,
antihypertensives, and cardiac medication) had been supplied for
at least 180 days, and/or at least two specialty visits to a cardi-
ologist had taken place. The use of 3 dispensings for eye drugs
(ATC code S01) or hospitalization for cataract surgery (ICD-
9-CM codes: 362, 366, 2505) was also assigned complication
stage 1. Stage 2 was assigned if hospitalization for major
ischemic heart disease, cerebrovascular accident, or peripheral
artery disease was recorded. Hospitalizations for foot, toe and
ankle amputations (procedure codes: 58480, 58470, 58469,
58450, 8462) were also assigned complication stage 2. The
frequency of diabetic complications attributed to DM was
estimated as the difference between the frequency of complica-
tion stages 1 and 2 among patients and that frequency among
controls.
Treatment
To estimate the number of pharmacologically treated DM
patients on a yearly base, the number of DM patients with at
least one dispensing of insulin (ATC code A10A), oral glucose-
lowering drugs (OGLDs; ATC code A10B), or cardiovascular
drugs (ATC chapter C) was determined. Among controls, the
number of subjects with at least one dispensing of cardiovascular
drugs was determined. These dispensings were considered not
attributable to DM. Cardiovascular treatment attributed to DM
in a given year was estimated as the number of patients with DM
with at least one dispensing for cardiovascular drugs, minus the
number of control subjects with at least one dispensing for car-
diovascular drugs in that year.
Diabetes-Related Cost
Direct diabetes-related cost was estimated based on annual cost
of treatment with insulin, OGLD, and cardiovascular drugs, and
on annual DM-related hospitalization costs. Cost related to
treatment with insulin and OGLD were considered among
patients with DM only; these costs among control subjects were
assumed to be negligible. Cost related to treatment with cardio-
vascular drugs attributed to DM was calculated as cost of car-
diovascular drugs dispensed to patients with DM minus cost of
cardiovascular drugs dispensed to control subjects. Cost of hos-
pitalizations attributed to DM was calculated as cost of hospi-
talizations of patients with DM minus cost of hospitalizations
of control subjects. Annual hospitalization cost estimates were
derived from admission costs. To calculate admission costs, the
costs of hospital charges were calculated per hospital and sum-
marized. These charges included admission day cost, the costs of
diagnostic and therapeutic procedures, and the specialist’s fee
for procedures, tests, operations, and visits. Admission day costs
were the costs of a single hospital and year-speciﬁc admission day
and included all costs not related to visits to medical specialists or
procedures [13–15]. All costs were based on charges made to
third-party payers, i.e. insurers or HMOs.
Statistical Analysis
Annual prevalence and cost estimates were extrapolated to
Dutch national estimates using direct standardization. The esti-
mates were stratiﬁed by gender and 5-year age groups. These
numbers were extrapolated to the 2004 national age and gender
distribution in The Netherlands by multiplying them with the
ratio of the number of inhabitants in The Netherlands divided by
the inhabitants covered by the PHARMO RLS per gender and
5-year age group [16]. Statistical signiﬁcance for differences in
proportions of patients over time was tested by the chi-square
test. A P-value of 0.05 or less was considered statistically signiﬁ-
cant. All data were analyzed using SAS programs organized
within SAS Enterprise Guide version 3.0 (SAS Institute Inc., Cary,
NC, USA) and conducted under UNIX using SAS version 9.1.
Results
Characteristics of Patients and Controls
Table 1 shows the characteristics of the 641,200 patients with
DM and their matched controls in 2004. In that year, 90.6% of
patients (and matched controls) were 40 years or older and
46.3%were male. Among patients with DM, 4568 (71.2%) were
classiﬁed as having complication stages 1 and 2. Among the
matched controls, this was 2869 (44.7%). Subtracting these fre-
quencies among the controls from the frequencies among the
patients yielded a frequency of patients with complications
attributed to DM of 1699 (26.5%). Among patients with DM,
1622 (25.3%) used insulin and 3869 (60.3%) OGLD. Cardio-
vascular (CV) drugs were used by 4489 (45.0%) patients and
617 (40.8%) controls; subtracting yielded 1871 (29.2%) patients
treated with CV drugs attributed to DM.
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Prevalence of DM and Macrovascular Complications
Among the total population in The Netherlands (16,000,000),
the prevalence of DM increased from 2.8% in 2000 to 4.0% in
2004. More speciﬁcally, the prevalence of DM in The Nether-
lands increased gradually from 454,000 in 2000 to 641,000 in
2004. Figure 1 shows this increase from year to year, by diabetic
complication stage (as attributed to DM). Although the absolute
number of patients with DM in diabetic complication stage 0
increased, the proportion of patients in stage 0 decreased from
76.4% in 2000 to 73.5% in 2004. Overall, the proportion of
patients with complications (stage 1 and 2) among all diabetics
increased from 23.6% in 2000 to 26.5% in 2004. The propor-
tion in diabetic complication stage 1 remained approximately
stable and the proportion in diabetic complication stage 2
increased from 4% in 2000 to 6% in 2004. Comparing 2004
with 2000, the changes over time were statistically signiﬁcant
(P < 0.001).
Treatment
Table 2 shows the number of pharmacologically treated DM
patients on a yearly base from 2000 to 2004. Comparing 2004
with 2000, the changes over time were again statistically signiﬁ-
cant (P < 0.001). Whereas the proportion of patients treated with
insulin decreased from 27.3% in 2000 to 25.3% in 2004, the
proportion of patients treated with OGLD increased from 55.7%
in 2000 to 60.4% in 2004. The absolute number of patients
treatedwithOGLD increasedwith 134,000 from253,000 in 2000
to 387,000 in 2004; this is equivalent to an increase of 53%.
The number of patients with DM treated with CV drugs
increased from 262,000 patients in 2000 to 449,000 patients in
2004, or an increase of 71%. During this period, however, the
number of control subjects treated with CV drugs (i.e., consid-
ered not attributable to DM) also increased with 73% from
151,000 to 262,000. Combining these numbers results in
111,000 patients treated with CV drugs attributable to DM in
2000 and 187,000 in 2004, or an increase of 68%.
DM-Related Cost
Annual direct cost estimates of treatment with insulin, OGLD,
cardiovascular drugs, and annual hospitalization cost estimates
are shown in Table 3. Cost estimates are given for patients with
DM, control subjects as well as estimates of direct treatment cost
attributed to DM. Total direct treatment costs of patients with
DM increased from €717,430,000 in 2000 to €1,430,726,000 in
2004. Most of these costs were related to hospitalizations for
DM (€508,813,000 in 2000 and €1,016,858,000 in 2004). Nev-
ertheless, the total direct treatment costs of control subjects
increased from €275,123,000 to €608,392,000 during this
period. Combining these costs resulted in direct treatment
cost attributed to DM (i.e., €442,308,000 for 2000 and
€822,333,000 in 2004). The largest contribution to this estimate
was direct treatment cost related to hospitalizations (i.e.,
€272,581,000 [62%] in 2000 and €535,672,000 [65%] in 2004).
Overall, per DM patient, the cost of direct treatment attributed
to DM increased from €974 in 2000 to €1283 in 2004, or an
increase of 32%. Per 100 members of the total population, this
increase was from €2764 in 2000 to €5140 in 2004, or an
increase of 86%.
Discussion
In The Netherlands, among the total population, the prevalence
of DM increased from 2.8% in 2000 to 4.0% in 2004. Severe
cardiovascular complications attributed to diabetes increased
from 18,000 to 39,000 patients. Nevertheless, the number of
patients treated with antidiabetic drugs has increased less. Cost
attributed to DM almost doubled, mainly because of costs
related to hospitalizations for DM. In absolute terms, the cost
associated with drug treatment and hospitalizations of patients
with DM was €1.4 billion in 2004, but at the same time, cost of
cardiovascular drug treatments and hospitalizations among
control subjects exceed €600 million. The direct treatment cost
that we attributed to DM was therefore limited to €822 million
in 2004.
This is one of the few studies that estimated the year-by-year
prevalence estimates of DM and its associated costs in “real-life”
population-based setting. Our observations are in line with both
international and national observations that demonstrate a
strong increase in the prevalence of DM [1,2,17]. Nevertheless,
in our study, the advent of new patients with type 2 DM appears
to remain in balance with patients progressing from stage 0 to
stage 1 and 2. Preventive efforts to diagnose and treat early DM
have apparently succeeded in catching up with the increased
inﬂux of new, uncomplicated cases with aging, although a
decrease was not achieved. This implies a strong achievement
with potentially large societal cost-saving impact. Nonetheless,
these efforts have not been able to avoid a substantial number of
patients progressing to complication stages 1 and 2. This is in line
with ﬁndings from other studies [18,19].
Our results suggest that an increase in the proportion of
complicated cases alone should not be held responsible for the
increase in the clinical burden of diabetes currently observed. The
Table 1 Characteristics of patients with diabetes mellitus in the
PHARMO database, and extrapolated after standardization to The
Netherlands in 2004
Characteristic
Patients with
diabetes mellitus
Age- and gender-
matched controls
n
(¥100) %
n
(¥100) %
n 6412 100.0 6412 100.0
Age group
0–14 73 1.1 73 1.1
15–39 525 8.2 525 8.2
40–64 3292 51.3 3292 51.3
65+ 2522 39.3 2522 39.3
Gender male 2967 46.3 2967 46.3
Cardiovascular complication stage*
All stages 6412 100.0 6412 100.0
Stage 0 1843 28.7 3543 55.3
Stage 1 3849 60.0 2536 39.6
Stage 2 719 11.2 333 5.2
Cardiovascular complication stage,
attributed to diabetes mellitus†
All stages 6412 100.0 6412 100.0
Stage 0 4712 73.5 6412 100.0
Stage 1 1313 20.5 0 0.0
Stage 2 386 6.0 0 0.0
Treatment‡
Insulin 1622 25.3 0 0.0
OGLD 3869 60.3 0 0.0
CV 4489 70.0 2617 40.8
Treatment, attributed to diabetes
mellitus†
Insulin 1622 25.3 0 0.0
OGLD 3869 60.3 0 0.0
CV 1871 29.2 0 0.0
*As deﬁned in reference 12.
†As deﬁned in the Methods.
‡Percentages add up to more than 100% because patients used more than one treatment.
Frequency of cardiovascular disease among matched controls subtracted from number of
patients with diabetes in complication stages 1 and 2 as explained in the Methods.
CV, cardiovascular drugs; n, number of subjects; OGLD, oral glucose-lowering drugs.
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assumption that we made in calculating these ﬁgures, however,
was that OGLD treatment among control subjects without DM
should be set at zero. This may not correspond to the everyday-
life experience, that subjects who are at risk of developing DM
are often treated with these drugs to prevent progression to
clinically manifest DM. Nevertheless, one may argue that these
OGLD treatments and the costs associated with them should be
attributed to the disease burden and economic burden of DM,
regardless of whether the diagnosis includes prediabetes.
Our results showed an increase of costs attributed to DM over
the period 2000 to 2004. This trend is also observed in many
studies investigating the economic burden of diabetes in both
Europe and the United States [18–20] and remains a very impor-
tant issue [17]. From Tables 2 and 3, it can be derived that this
increase in costs is mainly caused by the increase in the prevalence
of DM.Nevertheless, we realize that this increase cannot be solely
attributed to the increase in DM patients. For instance, unit prices
increased and new glucose-lowering therapies have entered the
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Figure 1 Prevalence of diabetes mellitus (DM) in the PHARMO database and the distribution of complication stages (attributed to DM) among prevalent diabetes
patients during 2000–2004.
Table 2 For the period 2000–2004, annual numbers of subjects treated with insulin, OGLD and cardiovascular medication are shown for patients with
diabetes mellitus and control subjects. Furthermore the numbers of patients treated, attributed to diabetes mellitus, are shown
Treatment
2000 2001 2002 2003 2004
n*
¥1000 %
n*
¥1000 %
n*
¥1000 %
n*
¥1000 %
n*
¥1000 %
Patients with diabetes mellitus
All† 454 100.0 510 100.0 546 100.0 591 100.0 641 100.0
Insulin 124 27.3 139 27.3 145 26.6 153 25.9 162 25.3
OGLD 253 55.7 285 55.9 314 57.5 350 59.2 387 60.4
CV‡ 262 55.7 306 60.0 341 62.5 389 65.8 449 70.0
Control subjects
All† 151 100.0 175 100.0 194 100.0 221 100.0 262 100.0
Insulin 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
OGLD 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
CV‡ 151 100.0 175 100.0 194 100.0 221 100.0 262 100.0
Treatment attributed to diabetes mellitus
Insulin 124 27.3 139 27.3 145 26.6 153 25.9 162 25.3
OGLD 253 55.7 285 55.9 314 57.5 350 59.2 387 60.4
CV‡ 111 24.4 131 25.7 147 26.9 168 28.4 187 29.2
*n, number of subjects extrapolated to The Netherlands; OGLD, oral glucose-lowering drugs; CV, cardiovascular drugs.
†Numbers within treatment groups add up to more than total because of multiple treatments per patient.
‡Number of patients with diabetes mellitus treated with cardiovascular drugs minus number of control subjects treated with cardiovascular drugs.
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market during this period. We did not correct for these factors
because therapies on the market in 2004 were different as com-
pared with those in 2000. We did not include data on the costs of
GP visits. Nevertheless, in The Netherlands, these visits are rather
inexpensive as compared to the very expensive hospitalizations.
The largest part of the costs for DM was determined by hospital-
izations for complications (65%), followed by glucose-lowering
therapies. This is conﬁrmed by other studies [17–19]. Comparison
of the costs attributed to DM as assessed in PHARMO for 2004
(€822 million) with the costs reported by the Dutch National
Institute for Public Health and the Environment (€832 million)
shows that these costs are approximately the same, whereas the
latter included GP visits [2].
A limitation of this study is the fact that macrovascular and
microvascular complications of DM had to be summarized in a
composite complications score. Although the vast majority of
complications in this population (>90% of patients were aged
>40 years and likely to have type 2 DM) probably comprised
macrovascular complications, the degree of underreport of
microvascular complications remains uncertain. This is in part
explained by the low degree of registration of microvascular
complications in clinical practice [21]. This study therefore calls
for further investment into systematic monitoring of eye and foot
problems with DM. What also should me mentioned is the fact
that the database included noninstitutionalized study subjects
(approximately 1% of the patients under study were nursing
home residents). It was therefore not possible to generalize con-
clusions toward this population. Another limitation was that for
the matching procedure, no data were available regarding social
economic status. Furthermore, we did not test for differences in
the outcome variables for the diabetes and nondiabetes groups.
In our opinion, this was not relevant as it was not the intention
of our study to compare differences between patients and con-
trols. We deﬁned a control group to estimate the “background”
costs to determine the costs attributed to DM. Nevertheless, if
this had been our intention then we had to analyze our data by
pooling the matched samples. Another limitation might be that
identiﬁcation of diabetics (not on medication) from the hospital-
ization events is problematic because it biases the risk of
hospitalization upward relative to the comparison group. Nev-
ertheless, we checked our data and found that on average 0.4%
of the diabetics was included solely on hospitalization. As this
percentage is rather small, we think the inﬂuence of this potential
bias is negligible. Finally, we only investigated pharmacological
treatment of DM and we realize that this is nowadays only one
aspect of diabetes treatment. Nevertheless, data on, for instance,
diet and physical activity were not available in our database.
However, we know from literature that the group of patients that
manages their diabetes on the long-term with only diet and
physical activity is rather small [22].
The increased prevalence of uncomplicated DM, which
stands out as an evident result, has several implications. Whereas
patients in the past have received a diagnosis of “cardiovascular
disease,” they may have received a diagnosis of “diabetes with
cardiovascular complications” in more recent years because of
increased awareness and diagnostic suspicion of diabetes. Dutch
national guidelines for preventive treatment in the primary-care
setting recommend blood glucose screening on an “ad hoc” basis
among individuals at high risk for cardiovascular disease [5].
This practice may lead to large variations in prevalence between
countries and regions according to individual physicians’ screen-
ing policy. As an example of this, regional specialized screening
programs, for example the Hoorn study, have led to substantially
higher prevalence estimates than estimates based on Dutch
national registration programmes [23]. The potential economic
savings that such programmes could achieve are substantial.
Nevertheless, these economic implications should be considered
in the light of the “background” costs in the general population
that will be made anyway because of an increasing burden of
cardiovascular disease in an aging population.
In conclusion, the ﬁndings of this study show that preventive
diagnostic and treatment efforts have succeeded in catching up
with the increased inﬂux of new diabetes patients. Nevertheless,
these efforts did not prevent direct costs associated with the use of
Table 3 Annual direct treatment cost of treatment with insulin, oral glucose-lowering drug (OGLD), cardiovascular drugs and hospitalization costs in
The Netherlands attributed to diabetes mellitus, 2000–2004
Cost type
2000 2001 2002 2003 2004
euros ¥ 1000 euros ¥ 1000 euros ¥ 1000 euros ¥ 1000 euros ¥ 1000
Direct treatment cost of patients
with diabetes mellitus
All* 717,430 878,515 1,039,217 1,182,210 1,430,726
Insulin treatment 66,358 80,176 84,919 88,370 99,062
OGLD treatment 33,538 41,752 47,811 54,055 65,047
CV treatment 113,721 143,820 168,358 193,080 204,759
Hospitalizations† 503,813 612,767 738,130 846,705 1,061,858
Direct treatment cost of control
subjects
All* 275,123 37,195 428,673 493,737 608,392
Insulin treatment 0 0 0 0 0
OGLD treatment 0 0 0 0 0
CV treatment 43,890 56,022 65,292 74,673 82,207
Hospitalizations† 231,233 315,173 363,381 419,064 526,186
Direct treatment cost attributed
to diabetes mellitus
All* 442,308 507,321 610,544 688,473 822,333
Insulin treatment 66,358 80,176 84,919 88,370 99,061
OGLD treatment 33,538 41,752 47,811 54,055 65,047
CV treatment‡ 69,832 87,799 103,065 118,472 122,552
Hospitalizations† 272,581 297,594 374,749 427,641 535,672
*Does not always add up to the total because of rounding.
†Hospitalizations as deﬁned in the Methods.
‡Cost of diabetes mellitus-related hospitalizations of patients with diabetes mellitus minus cost of hospitalizations of control subjects.
CV, cardiovascular drugs.
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antidiabetic drugs andwith hospitalizations from doubling. These
costs should however be offset to “background” costs in the gene-
ral population that will be made anyway because of an increasing
burden of cardiovascular disease in an aging population.
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